Direct factory supply of precision-engineered embolic microspheres, advanced dietary bio-actives, and cardiovascular formulations tailored for regional hospital tenders and pharmaceutical distributors.
Porto-Novo, the political capital of Benin, stands at a critical juncture in West Africa's epidemiological transition. Over the past two decades, public health data across the Ouémé Department indicates a rapid surge in non-communicable diseases (NCDs), particularly essential hypertension, ischemic heart disease, stroke, and secondary heart failure resulting from hypertensive heart disease.
Healthcare facilities across Porto-Novo—ranging from the Centre Hospitalier Universitaire Départemental (CHUD-Ouémé/Plateau) to private medical clinics—face mounting pressure to secure high-purity, bioequivalent, and cost-effective cardiovascular therapeutic agents. Uninterrupted supply chain resilience is mandatory to prevent therapeutic gap periods that jeopardize patient outcomes.
Key Market Driver: Benin’s Agence Béninoise de Régulation Pharmaceutique (ABRP) and West African Health Organization (WAHO) guidelines require strict adherence to WHO-GMP standards, Zone IVb stability protocols, and clear API traceability. Hangzhou Jeci Biochem Technology provides direct factory access to bridging these critical supply demands.
By utilizing the strategic maritime access point of Cotonou Autonomous Port coupled with direct transport corridors to Porto-Novo (RN3 highway network), our pharmaceutical shipments bypass intermediary markups. We ensure rapid customs clearance via standardized Certificate of Analysis (CoA), Drug Master Files (DMF), and WHO-GMP certifications.
Understanding why international procurement directors in West Africa partner with Hangzhou Jeci Biochem for bulk cardiovascular APIs and advanced formulations.
China accounts for over 40% of the world's Active Pharmaceutical Ingredient (API) supply. Hangzhou Jeci Biochem leverage integrated raw material synthesis clusters in Zhejiang Province, ensuring complete cost containment and raw material availability for Angiotensin-Converting Enzyme (ACE) inhibitors, Beta-Blockers, and Calcium Channel Blockers.
Our facilities implement ICH Q7 quality guidelines. Every batch undergoes rigorous High-Performance Liquid Chromatography (HPLC), Mass Spectrometry (LC-MS), and heavy metal limit tests, fulfilling all regulatory filings required by Benin's Ministry of Health and international auditing teams.
Whether delivering finished oral solid doses, liquid suspensions, or supplying advanced chemical precursors for local laboratory compounding, our flexible batch processing systems allow for rapid scale-up from pilot trials (10kg) to industrial commercialization (multi-ton lots).
A global leader in active pharmaceutical ingredients, intermediates, and high-tech bio-nutritional products.
Hangzhou Jeci Biochem Technology Co., Ltd. is located in Hangzhou, Zhejiang Province. We are committed to sales of active pharmaceutical ingredients, pharmaceutical intermediates, nutritional products and food additives, cooperative R & D, custom manufacturing, sales and service as well as import of these kinds of materials.
In China, we have a strong collaborative R&D team, working in depth with new drug research institutes and multiple custom processing plants. We have very good domestic sales channels and have long-term relationships with domestic companies, including product applications, technology transfer, product supply, custom processing, and exclusive agents for multiple products in multiple regions. In addition, we also provide factory quality management system certification consulting services.
Internationally, we have long-term trade relations with India, Southeast Asia, South Korea, Japan and other markets, and provides products in the whole process of market and sales services. At the same time, we also provide product registration, consulting and sales channel expansion services for overseas companies in the Chinese market.
Our drugs, APIs, and intermediates are widely applied across multiple industrial and pharmaceutical domains, ensuring compliance with global pharmacopeias (USP, EP, IP, BP):
We are able to assemble and produce larger quantities of intermediates and provide some advanced, convenient manufacturing capabilities, including batch processing and customization.
For the company's main product intermediates: We can maximize our advantages, meet the requirements of most customers and complete the task within the specified time limit.
Adapting next-generation therapeutic delivery systems for emerging medical markets like Porto-Novo.
The shift toward minimally invasive interventional cardiology and vascular radiology demands precision microspheres. Drug-eluting embolic microspheres (such as our specialized UAE lines) allow localized chemo-embolization, reducing systemic cardiotoxicity while expanding treatment options in regional African referral centers.
To overcome patient compliance barriers in outpatient care across Porto-Novo, dual and triple fixed-dose combinations (e.g., ACE inhibitor + Diuretic) represent the benchmark in modern hypertension management. Our manufacturing plant provides standardized co-formulated APIs with uniform dissolution profiles.
Cardiovascular pathology is not restricted to human medicine. Canine Myxomatous Mitral Valve Disease (MMVD) and Dilated Cardiomyopathy (DCM) require palatable, specialized Enalapril and Pimobendan formulations. Hangzhou Jeci Biochem provides dual-stream manufacturing for both human and veterinary health sectors.
Explore our full array of animal health therapeutics, human bio-actives, interventional embolic microspheres, and custom API formulations available for direct factory export to Porto-Novo.
Expert insights on regulatory compliance, ocean/air shipping parameters, batch quality assurance, and direct factory custom synthesis.
Expand your pharmaceutical distribution network in Porto-Novo and West Africa. Contact our technical sales team for factory-direct quotations, COA requests, and dossier support.
SJ medical